This is the single most important page in this guide. Regenerative medicine marketing language — "FDA-registered," "FDA-compliant," "cutting-edge," "biologic" — often sounds like regulatory approval without actually being regulatory approval.
What's Actually FDA-Approved
As of this writing, the only FDA-approved stem cell products in the United States are blood-forming (hematopoietic) stem cells derived from umbilical cord blood, approved specifically for disorders affecting blood production — leukemia, lymphoma, and similar conditions. Approval is always tied to a particular product and a particular use, not to "stem cells" or "MSCs" as a general category.
There are currently zero FDA-approved exosome products for any medical or aesthetic use. This is not a gap that's about to close quietly — it reflects the FDA's position that exosome products meet the definition of a drug and/or biological product requiring the same premarket review as any other new drug.
Why "FDA-Registered" Doesn't Mean "FDA-Approved"
This is the single most common point of confusion in this field:
- FDA-approved: the product has gone through formal premarket review demonstrating safety and effectiveness for a specific use.
- FDA-registered: a facility has registered its existence with the FDA — a basic administrative step that says nothing about whether any specific product has been reviewed or approved.
- "Minimally manipulated, homologous use" (Section 361): a narrow pathway that allows certain tissue products without premarket approval, but only if minimally processed and used for its original biological function. Most exosome products fail this test because the isolation and concentration process is considered "more than minimal manipulation," and most marketed uses (skin rejuvenation, joint pain, anti-aging) are unrelated to the tissue's original function.
The Enforcement Reality
This isn't a theoretical regulatory gray area — it's an active enforcement priority:
- The FDA has issued numerous warning letters to exosome manufacturers and clinics since 2019, with the pace increasing through 2024–2026, citing the marketing of unapproved new drugs and unlicensed biological products.
- In 2024, a stem cell product distributor was sentenced to 36 months in federal prison after pleading guilty to introducing an unapproved new drug into interstate commerce; the products were linked to documented bacterial infection hospitalizations across multiple states.
- The CDC has separately documented serious adverse events — including infections, allergic reactions, and tumor formation — associated with unapproved products.
- The FTC has pursued enforcement actions against clinics for unsubstantiated claims, obtaining permanent bans and monetary penalties in 2024–2025 cases.
A Note on Sourcing and Quality Control
Because most exosome and non-hematopoietic stem cell products fall outside FDA premarket review, there's no independent verification of what's actually in a given vial — concentration, purity, sterility, and even whether the product contains functional exosomes at all can vary significantly between sources. The International Society for Extracellular Vesicles has published detailed technical standards (known as MISEV) specifically because, in their words, even scientists struggle to verify the contents and function of a given EV preparation.
Key Takeaway
A transparent clinic should be able to explain exactly which regulatory pathway applies to what they're offering — and the difference between "FDA-registered" and "FDA-approved" is not a technicality. It's the difference between a product that has been reviewed for safety and one that hasn't.